Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.

Christopher G C A JacksonTak HungEva SegelovPaula BarlowHans PrenenBlair McLarenNoelyn Anne HungKatriona ClarkeTsu-Yi ChaoMing-Shen DaiHsien-Tang YehDavid L CutlerDouglas KramerJimmy HeJay ZhiWing-Kai ChanRudolf KwanSanjeev Deva

Published in: British journal of clinical pharmacology (2021)

GMR for AUC was within the predefined acceptable range of 80-125% for demonstrating equivalence. oPac+E is tolerable and there is no evidence of P-gp induction with repeat administration. With further study, oPac+E could be an alternative to IVP.

Keyphrases

advanced cancer
palliative care
open label
clinical trial
double blind
placebo controlled
high dose
randomized controlled trial
chemotherapy induced